Trial Profile

A study of iopofosine I 131 for the treatment of mycosis fungoides

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 03 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Jun 2024 New trial record
29 May 2024 According to a Cellectar Biosciences media release, company announced a strategic partnership with City of Hope Cancer Center which will focus on the clinical development of Cellectar's lead radioconjugate asset, iopofosine I 131, in mycosis fungoides (MF)
29 May 2024 According to a Cellectar Biosciences media release, this investigator sponsored trial initiation is planned for late 2024 or early 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com